This course has expired. View available courses.
Oncology
Enhancing Oncology Care for Breast and Lung Cancer Patients in the Kingdom of Saudi Arabia
The objective of this program is to help educate and support pharmacists in the Kingdom of Saudi Arabia in understanding the current landscape of approved therapies for breast cancer and lung cancer, with a focus on targeted therapy and immunotherapy. The program also describes how pharmacists can collaborate within a multidisciplinary team to support patients throughout their oncology journey, from diagnosis through treatment and follow-up.
DURATION
1 hr
PROFESSION
Pharmacy
# OF CREDITS
0
ACCREDITATION
Unaccredited
EXPIRY DATE
2024-07-26
The incidence of both breast cancer and lung cancer is rising in the Kingdom of Saudi Arabia (KSA). An aging population and a growing popularity of smoking are contributing factors to the predicted increase in the number of cases of both these types of cancer. Pharmacists can play a role in patient education to contribute to efforts to prevent lung and breast cancer.
Many different treatment approaches exist for both breast and lung cancer. The objective of this program is to help educate and support pharmacists in the Kingdom of Saudi Arabia in understanding the current landscape of approved therapies for breast cancer and lung cancer, with a focus on targeted therapy and immunotherapy. The program also describes how pharmacists can collaborate within a multidisciplinary team to support patients throughout their oncology journey, from diagnosis through treatment and follow-up.
This program is supported by Novartis.
Faculty
Majed Alshamrani, PharmD, MBA, BCPS
Meteb Al-Foheidi, MD
Nora A. Alkhudair, Assistant Professor, PharmD
Hamed Alhussaini, MD
Learning objectives
Upon completion of this continuing education program, participants will be better able to:
- List the risk factors for breast cancer and identify patients who are at high risk.
- Describe the role of targeted therapy (i.e., CDK inhibitors) in breast cancer treatment.
- Discuss the role of targeted therapy and immunotherapy in the treatment of lung cancer.
- Describe the recommendations for the management of lung cancer per the Saudi Lung Cancer Management Guidelines.
- Collaborate within a multidisciplinary team throughout a patient’s oncology journey, from diagnosis through treatment and follow-up.
#
of credits: 0
Duration: 1 hr
FAQs & HELP
MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.
All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.
The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
If you are interested in learning more about supporting one of our programs, please contact us.
If you are interested in working with MDBriefCase Group as a writer or committee member, please contact us.
To access the MDBriefCase Group privacy policy, please click here.
No, registration with MDBriefCase is free!
To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.
If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.
Please note: if you submitted multiple password resets, only the link on the most recent email is valid.
You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.
1 hr
Duration
Pharmacy
Profession
0
# of credits
Learning Objectives
Upon completion of this continuing education program, participants will be better able to:
- List the risk factors for breast cancer and identify patients who are at high risk.
- Describe the role of targeted therapy (i.e., CDK inhibitors) in breast cancer treatment.
- Discuss the role of targeted therapy and immunotherapy in the treatment of lung cancer.
- Describe the recommendations for the management of lung cancer per the Saudi Lung Cancer Management Guidelines.
- Collaborate within a multidisciplinary team throughout a patient’s oncology journey, from diagnosis through treatment and follow-up.
Unaccredited
ACCREDITATION
Oncology
Learning Category
Breast Cancer
Topic
0
Price
2024-07-26
Expiry Date
MENA
Region/Language
Course Description
The incidence of both breast cancer and lung cancer is rising in the Kingdom of Saudi Arabia (KSA). An aging population and a growing popularity of smoking are contributing factors to the predicted increase in the number of cases of both these types of cancer. Pharmacists can play a role in patient education to contribute to efforts to prevent lung and breast cancer.
Many different treatment approaches exist for both breast and lung cancer. The objective of this program is to help educate and support pharmacists in the Kingdom of Saudi Arabia in understanding the current landscape of approved therapies for breast cancer and lung cancer, with a focus on targeted therapy and immunotherapy. The program also describes how pharmacists can collaborate within a multidisciplinary team to support patients throughout their oncology journey, from diagnosis through treatment and follow-up.
This program is supported by Novartis.
Faculty
Majed Alshamrani, PharmD, MBA, BCPS
Meteb Al-Foheidi, MD
Nora A. Alkhudair, Assistant Professor, PharmD
Hamed Alhussaini, MD
Accreditation
1 hr
Duration
0
Price
0
# of credits
